Skip to content

LSD: all studies

Page 212 of 282: studies 2,111 to 2,120 of 2,815, newest first. Back to the LSD overview

Research

NBOMe Toxicity and Fatalities: A Review of the Literature

Transformative Medicine March 1, 2022 Matthew Lipow, Syed Kaleem, Eduardo D. Espiridion

In the decade since the introduction of the novel synthetic hallucinogen NBOMe into the consumer market, this drug has become an increasingly prevalent, yet poorly understood cause of altered mental status (AMS) resulting in hospitalization. In this literature review, we conducted a PubMed query for mentions of NBOMe ingestion since Suzuki et al.’s publication of their 2015 review. Among...

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility

Journal of Psychopharmacology March 1, 2022 Max Wolff, Lea J. Mertens, Marie Walter et al. 57 citations

Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effects and corresponding changes in psychological flexibility. Underlying psychological mechanisms are insufficiently understood. Aim: The purpose of this study was the validation of a psychological model of acceptance/avoidance-promoting psychedelic...

The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review

Journal of Psychoactive Drugs February 28, 2022 Andrew Hodge, Suporn Sukpraprut‐braaten, Matthew R Narlesky et al. 47 citations

There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the "Psychedelic Renaissance." This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain...

Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study

Scientific Reports February 16, 2022 Grant Jones, Matthew K. Nock 44 citations

Abstract Cocaine Use Disorder (CUD) is a significant public health problem associated with elevated morbidity and mortality within the United States. Current behavioral treatments have limited efficacy and there are currently no FDA approved pharmacological treatments for CUD. Classic psychedelics might be associated with lowered odds of substance misuse and may effectively treat various forms...

The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review

Journal of Pain and Symptom Management February 11, 2022 Lucas Oliveira Maia, Yvan Beaussant, Ana Cláudia Mesquita Garcia 59 citations

ContextPeople affected by serious illness usually experience suffering in its various dimensions, not only in the physical but also in the psychosocial and spiritual aspects. The interest in psychedelic-assisted therapies as a potential new therapeutic modality has increased since evidence suggests a significant impact of their use on the outcomes of patients with serious illness.ObjectivesTo...

Hallucinogen chemistry guides antidepressant drug discovery

C&EN Global Enterprise February 7, 2022 Bethany Halford

Scientists have long sought the secrets of the 5-HT 2A serotonin receptor—a central nervous system receptor that binds hallucinogenic compounds, including LSD and psilocybin. Many hope to discover why these molecules cause hallucinations when they bind to 5-HT 2A while other compounds that bind to the receptor, including serotonin, do not. LSD and psilocybin have been shown to treat mood...

DOI: 10.1021/cen-10005-leadcon (opens in new tab) Hallucinogen Antidepressant Drug discovery Pharmacology

Ethics Committees Reimagined

Psychiatric News January 28, 2022 Claire Zilber

Back to table of contents Previous article Next article Ethics CornerFull AccessEthics Committees ReimaginedClaire Zilber, M.D.Claire Zilber, M.D.Published Online:28 Jan 2022https://doi.org/10.1176/appi.pn.2022.2.25The APA and district branch (DB) ethics committees used to stay busy processing complaints from patients, their family members, and colleagues about members who allegedly engaged in...

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

Frontiers in Pharmacology January 27, 2022 Athanasios Markopoulos, Antonio Inserra, Danilo de Gregorio et al. 44 citations

Recent clinical and preclinical evidence points towards empathogenic and prosocial effects elicited by psychedelic compounds, notably the serotonin 5-HT 2A agonists lysergic acid diethylamide (LSD), psilocybin, N,N-Dimethyltryptamine (DMT), and their derivatives. These findings suggest a therapeutic potential of psychedelic compounds for some of the behavioural traits associated with autism...

Shedding Light on Classic Psychedelics and Self-Harm.

The Journal of Clinical Psychiatry January 18, 2022 Dan Grossman, Peter S. Hendricks

A research on classic psychedelic–assisted treatments continues to expand, we can expect that findings will sometimes challenge or elucidate long-held conventional beliefs about the purported dangers of these substances. One such notion has been that they precipitate suicidality1 and other self-harm behaviors (eg, jumping off of buildings believing one can fly, walking in front of traffic2) in...